

Policy on working with pharmaceutical and biotechnology companies

Date 12.09.21

Reviewed by the board on 06.10.21

Introduction

Pharmaceutical and biotechnology companies play a central role in developing and delivering new diagnostic tests, therapies and treatments to patients with prostate cancer. By working with these industries, we have an opportunity to support and speed the development of innovative new treatments and tests that meet the needs and preferences of prostate cancer patients. Collaboration can take many forms, ranging from donations to working together and sharing advice and expertise.

All of our work with companies complies with this policy, and in all dealings with companies we will continue to uphold our commitment to transparency, impartiality and independence. This policy takes into account the Association of Medical Research Charities' (AMRC) publication, "An Essential Partnership Principles & Guidelines for Working with Industry" 2014. It is supported by a wider Corporate Partnerships Policy and complies with the Charity Commission guidelines 'Fundraising through Partnerships with Companies'.

How we work with companies

PCR's policy for working with the medicine, device, diagnostics, allied and private healthcare industries is based upon the following core principles:

1. **Independence:** PCR will always maintain its independence. We will remain free to comment, both positively and negatively in relation to the company, in the interest of people affected by prostate cancer.
2. **Integrity:** PCR will always act with honesty and integrity. We expect adherence to similarly high standards by all companies with whom we develop relationships.
3. **Transparency:** PCR will be open about any collaboration and be able to account publicly for the associated activities and any exchanges of funding with, and from, pharmaceutical companies.

Taking into consideration these core principles, we only work with companies when:

- The company complies with the standards set out in the Association of British Pharmaceutical Industries (ABPI) Code of Practice, and in particular Clause 27 which relates to working with patient groups.
- We have carried out, and are satisfied with due diligence checks
- The terms of the collaboration or funding are clearly set out in a written agreement, signed by both parties
- Any intellectual property generated remains with the charity
- The collaboration will not result in one company gaining a competitive advantage over another
- Publications or products generated as a result of industry sponsorship carry our logo and source of funding is transparent
- The relationship/activity is not subject to any conditions that are unacceptable to, or prevent us from acting in the best interests of, people with or affected by Prostate cancer
- The company does not seek to influence the charities strategy, projects or activities, either explicitly or implicitly.

In order to maintain our independence, income received from pharmaceutical, biotechnology and allied companies will not normally exceed 30% of our total annual income. Should circumstances arise where this percentage is likely to be exceeded, approval of the Board will be sought prospectively.

No person acting on behalf of Prostate Cancer Research is permitted to accept a personal payment from any company. The charity will accept honoraria, fees and reimbursement of expenses provided the CEO is satisfied that participation is consistent with the terms of this policy.

ENDS

This policy is reviewed annually. Scheduled date of next review October 2022.